• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌发生过程中病因依赖的微生物组差异

Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development.

作者信息

Todorovic Nevena, Martinelli Serena, Nannini Giulia, Weiskirchen Ralf, Amedei Amedeo

机构信息

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.

出版信息

Int J Mol Sci. 2024 Dec 17;25(24):13510. doi: 10.3390/ijms252413510.

DOI:10.3390/ijms252413510
PMID:39769276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11677376/
Abstract

Chronic liver disease is characterised by persistent inflammation, tissue damage, and regeneration, which leads to steatosis, fibrosis, and, lastly, cirrhosis and hepatocellular carcinoma (HCC). HCC, the most prevalent form of primary liver cancer, is one of the leading causes of cancer-related mortality worldwide. The gut microbiota plays a fundamental role in human physiology, and disturbances in its critical balance are widely recognised as contributors to various pathological conditions, including chronic liver diseases, both infectious and non-infectious in nature. Growing interest in microbiota research has recently shifted the focus towards the study of intratumoural microbiota, referred to as the "oncobiome", which can significantly impact the development and progression of HCC. In this review, we discuss existing research and provide an overview of the microbiota influence on viral hepatitis, particularly in shaping the progression of liver disease caused by the hepatitis B and hepatitis C viruses. We also explore microbial dysbiosis and its contribution to the silent and dangerous progression of non-alcoholic fatty liver disease. Additionally, we address the impact of alcohol on the liver and its interaction with the microbiota, tracing the pathway from inflammation to cirrhosis and cancer. The review emphasises the most common etiologies of hepatocellular carcinoma.

摘要

慢性肝病的特征是持续的炎症、组织损伤和再生,这会导致脂肪变性、纤维化,最终发展为肝硬化和肝细胞癌(HCC)。HCC是原发性肝癌最常见的形式,是全球癌症相关死亡的主要原因之一。肠道微生物群在人体生理学中起着重要作用,其关键平衡的紊乱被广泛认为是导致各种病理状况的因素,包括本质上具有传染性和非传染性的慢性肝病。近年来,对微生物群研究的兴趣日益浓厚,研究重点已转向对肿瘤内微生物群(即“肿瘤微生物组”)的研究,它会对HCC的发生和发展产生重大影响。在这篇综述中,我们讨论了现有研究,并概述了微生物群对病毒性肝炎的影响,特别是在乙型肝炎病毒和丙型肝炎病毒引起的肝病进展过程中的作用。我们还探讨了微生物失调及其对非酒精性脂肪性肝病无声且危险进展的影响。此外,我们阐述了酒精对肝脏的影响及其与微生物群的相互作用,追溯了从炎症到肝硬化和癌症的发展路径。这篇综述强调了肝细胞癌最常见的病因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d10d/11677376/7210af6a1bb9/ijms-25-13510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d10d/11677376/7210af6a1bb9/ijms-25-13510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d10d/11677376/7210af6a1bb9/ijms-25-13510-g001.jpg

相似文献

1
Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development.肝细胞癌发生过程中病因依赖的微生物组差异
Int J Mol Sci. 2024 Dec 17;25(24):13510. doi: 10.3390/ijms252413510.
2
Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.肠道微生物失调通过肠-肝轴与肝细胞癌相关。
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):19-27. doi: 10.1016/j.hbpd.2018.11.002. Epub 2018 Nov 22.
3
Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.肝硬化导致肝癌患者肠道微生物群失调。
Cancer Med. 2020 Jun;9(12):4232-4250. doi: 10.1002/cam4.3045. Epub 2020 Apr 12.
4
New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.肠道微生物群在非酒精性脂肪性肝病及其相关肝癌中的新见解和治疗意义。
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.
5
Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.肝细胞癌中肠道微生物组的改变:发病机制的深入了解及临床前到临床研究结果。
APMIS. 2022 Dec;130(12):719-740. doi: 10.1111/apm.13282. Epub 2022 Nov 13.
6
Sirtuins and Gut Microbiota: Dynamics in Health and a Journey from Metabolic Dysfunction to Hepatocellular Carcinoma.沉默调节蛋白与肠道微生物群:健康中的动态变化以及从代谢功能障碍到肝细胞癌的历程
Cells. 2025 Mar 20;14(6):466. doi: 10.3390/cells14060466.
7
Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.肠道微生物群和氧化应激在非酒精性脂肪性肝病向肝癌进展中的作用:当前和创新的治疗方法。
Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3.
8
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.非酒精性脂肪性肝病与肠道微生物组。
Clin Liver Dis. 2016 May;20(2):263-75. doi: 10.1016/j.cld.2015.10.012. Epub 2015 Dec 24.
9
Gut microbiome in HCC - Mechanisms, diagnosis and therapy.肝癌中的肠道微生物组:机制、诊断与治疗。
J Hepatol. 2020 Feb;72(2):230-238. doi: 10.1016/j.jhep.2019.08.016.
10
The Gut Microbiome and Hepatocellular Carcinoma.肠道微生物组与肝细胞癌。
J Gastrointest Cancer. 2021 Dec;52(4):1314-1319. doi: 10.1007/s12029-021-00748-1. Epub 2021 Dec 6.

引用本文的文献

1
Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies.肠道微生物群与肝脏疾病中的肠-肝轴:从慢性病毒性肝炎到肝硬化、肝细胞癌及基于微生物群的治疗方法
Microorganisms. 2025 Apr 30;13(5):1053. doi: 10.3390/microorganisms13051053.

本文引用的文献

1
Intratumoral Microbiome: Foe or Friend in Reshaping the Tumor Microenvironment Landscape?肿瘤内微生物组:重塑肿瘤微环境景观的敌人还是朋友?
Cells. 2024 Jul 30;13(15):1279. doi: 10.3390/cells13151279.
2
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.健康与疾病中的肠-肝-胰轴相互作用:从微生物代谢产物的作用到创新的微生物群调控策略。
Biomedicines. 2024 Jun 24;12(7):1398. doi: 10.3390/biomedicines12071398.
3
Gut microbiome and metabolome signatures in liver cirrhosis-related complications.
肝硬化相关并发症的肠道微生物组和代谢组特征。
Clin Mol Hepatol. 2024 Oct;30(4):845-862. doi: 10.3350/cmh.2024.0349. Epub 2024 Jul 25.
4
Apolipoprotein H deficiency exacerbates alcohol-induced liver injury via gut Dysbiosis and altered bile acid metabolism.载脂蛋白H缺乏通过肠道菌群失调和胆汁酸代谢改变加剧酒精性肝损伤。
Biochim Biophys Acta Mol Cell Biol Lipids. 2024 Oct;1869(7):159535. doi: 10.1016/j.bbalip.2024.159535. Epub 2024 Jul 20.
5
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.非酒精性脂肪性肝病中的短链脂肪酸:短链脂肪酸作为治疗靶点的新前景
Heliyon. 2024 Feb 27;10(5):e26991. doi: 10.1016/j.heliyon.2024.e26991. eCollection 2024 Mar 15.
6
Identification of a novel FOXO3 agonist that protects against alcohol induced liver injury.鉴定一种新型 FOXO3 激动剂,可预防酒精性肝损伤。
Biochem Biophys Res Commun. 2024 Apr 16;704:149690. doi: 10.1016/j.bbrc.2024.149690. Epub 2024 Feb 17.
7
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.代谢相关脂肪性肝病:发病机制、诊断方法及治疗策略的选择性综述
Front Med (Lausanne). 2024 Jan 23;11:1291501. doi: 10.3389/fmed.2024.1291501. eCollection 2024.
8
Meta-analysis reveals obesity associated gut microbial alteration patterns and reproducible contributors of functional shift.荟萃分析揭示了肥胖相关的肠道微生物改变模式和功能转变的可重现贡献因素。
Gut Microbes. 2024 Jan-Dec;16(1):2304900. doi: 10.1080/19490976.2024.2304900. Epub 2024 Jan 24.
9
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.胆汁酸、肠道微生物群与肝细胞癌的治疗新视角。
Cancer Biol Med. 2023 Dec 23;21(2):144-62. doi: 10.20892/j.issn.2095-3941.2023.0394.
10
HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article.丙型肝炎病毒和肝细胞癌的探戈舞步——疾病复杂性的解析:一篇综述文章。
Int J Mol Sci. 2023 Nov 7;24(22):16048. doi: 10.3390/ijms242216048.